Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma

Leggi l'articolo originale


The approved combination of nivolumab and ipilimumab has demonstrated potent efficacy in the treatment of metastatic melanoma, with higher objective response rates (ORRs) and progression-free survival (PFS) as first-line treatment than either agent alone [1,2] and improvement of 3-year overall survival (OS) compared with ipilimumab [3]. However, few studies have evaluated the efficacy in patients with primary resistance to PD-1 inhibitors [4–7], and the usefulness and safety profile after anti-CTLA4 and/or anti-PD1 failure is still unclear.

Lascia un commento